Drug Type Small molecule drug |
Synonyms Carisbamate (USAN), Comfyde, JNJ-10234094 + [2] |
Mechanism Neurotransmitter receptor modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC9H10ClNO3 |
InChIKeyOLBWFRRUHYQABZ-MRVPVSSYSA-N |
CAS Registry194085-75-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06573 | Carisbamate |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epilepsy | NDA/BLA | US | - | |
Epilepsy | NDA/BLA | EU | - | |
Langer-Giedion Syndrome | Phase 3 | US | 28 Apr 2022 | |
Langer-Giedion Syndrome | Phase 3 | AR | 28 Apr 2022 | |
Langer-Giedion Syndrome | Phase 3 | AU | 28 Apr 2022 | |
Langer-Giedion Syndrome | Phase 3 | CO | 28 Apr 2022 | |
Langer-Giedion Syndrome | Phase 3 | DE | 28 Apr 2022 | |
Langer-Giedion Syndrome | Phase 3 | GR | 28 Apr 2022 | |
Langer-Giedion Syndrome | Phase 3 | IL | 28 Apr 2022 | |
Langer-Giedion Syndrome | Phase 3 | IT | 28 Apr 2022 |
Phase 1/2 | 11 | Placebo (Placebo) | seivyrxfre(hzvmubixlv) = rqajthacuy zpewpywzyg (iylswuinbi, eciknacvzf - bjjtksmjhz) View more | - | 02 Mar 2021 | ||
(Carisbamate) | seivyrxfre(hzvmubixlv) = wylwfljacp zpewpywzyg (iylswuinbi, tapxovxjqa - bcolkybnjd) View more | ||||||
Phase 3 | 547 | dcgjnxycqz(ouixhwlqlc) = Dizziness was the most common treatment-emergent adverse event, with a higher incidence (≥ 5% difference) in the combined carisbamate group (31%) than placebo (9%); the incidence was higher with carisbamate 1,200 mg (32%, n = 58) than with carisbamate 800 mg (30%, n = 53) gsmswhwyxx (aanmklzely ) | Negative | 01 Apr 2011 | |||